Add to Watchlist Create Alerts

Real-Time Last Update

Last Sale Cboe BZX Real-Time

Volume

CSL Seqirus Announces Third U.S. Government Award in Relation to Influenza A(H5N8) Candidate Vaccine

PR Newswire - Mon Aug 28, 2023

SUMMIT, N.J., Aug. 28, 2023 /PRNewswire/ -- CSL Seqirus, a business of CSL (ASX: CSL), was selected by the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response (ASPR) within the U.S. Department of Health and Human Services (HHS), to deliver one bulk lot of H5N8 A/Astrakhan antigen to the U.S. government. This acquisition of a bulk lot will increase BARDA's stockpile of vaccine to support rapid response in an associated influenza pandemic.

Read more at prnewswire.com

Provided Content: Content provided by PR Newswire. The Globe and Mail was not involved, and material was not reviewed prior to publication.

More from The Globe

investor newsletter

A change in market leadership may be imminent. Plus, an index-beating U.S. dividend portfolio strategy

Tensions rise in Silicon Valley over sales of startup stocks

inside the market

How pro money managers are balancing exposure to Canadian and U.S. stocks

At the open: North American stock markets rise as rate-cut hopes linger

The close: Wall Street sharply higher as nonfarm payrolls report strengthens case for rate cuts in both the U.S. and Canada

The close: Major North American indexes higher, led by Nasdaq, amid plethora of mixed earnings

international business

Trump awarded 36 million more Trump Media shares worth $1.8-billion after hitting price benchmarks

The close: Stocks mixed as Fed leaves investors guessing as to when rate cuts will arrive